_id
6919ebf43c536f8df23183b6
Ticker
NFX.LSE
Name
Nuformix plc
Exchange
LSE
Address
60 Gracechurch Street, London, United Kingdom, EC3V 0HR
Country
UK
Sector
Healthcare
Industry
Biotechnology
Currency
GBX
Website
https://www.nuformix.com
Description
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Last Close
2500
Volume
1748287
Current Price
0.272
Change
-2.0000000000000018
Last Updated
2025-12-30T11:18:34.829Z
Image
https://logo.clearbit.com/www.nuformix.com
Ipo Date
-
Market Cap
5274374
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-03-31
Revenue
-
Cost Of Revenue
14583
Gross Profit
-14583
Operating Expenses
376.67
Operating Income
-376
Interest Expense
-
Pretax Income
-376
Net Income
-376
Eps
-0.0002735818853866527
Dividends Per Share
-
Shares Outstanding
2109749903
Income Tax Expense
-
EBITDA
-362
Operating Margin
-
Total Other Income Expense Net
-
Cash
97911
Short Term Investments
-
Receivables
36867
Inventories
-
Total Current Assets
140344
Property Plant Equipment
0
Total Assets
1037172
Payables
229519
Short Term Debt
-
Long Term Debt
-
Total Liabilities
229519
Equity
807653
Bs_currency_symbol
GBP
Depreciation
14583
Change In Working Capital
-3.52
Cash From Operations
-391049
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
468750
Net Change In Cash
77701
Cf_currency_symbol
-
PE
-
PB
0.4628546170199331
ROE
-0.046554646611849396
ROA
-0.03625242486299283
FCF
-391049
Fcf Percent
-
Piotroski FScore
0
Health Score
41
Deep Value Investing Score
5.5
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2.5
Net Net Investing Score
2.5
Quality Investing Score
3
Value Investing Score
5.5
Quarters > 0 > quarter
2025-03-31
Quarters > 0 > income Statement > revenue
-
Quarters > 0 > income Statement > cost Of Revenue
14583
Quarters > 0 > income Statement > gross Profit
-14583
Quarters > 0 > income Statement > operating Expenses
376.67
Quarters > 0 > income Statement > operating Income
-376
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-376
Quarters > 0 > income Statement > net Income
-376
Quarters > 0 > income Statement > eps
-0.0002735818853866527
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
1374360
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-362
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
97911
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
36867
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
140344
Quarters > 0 > balance Sheet > property Plant Equipment
0
Quarters > 0 > balance Sheet > total Assets
1037172
Quarters > 0 > balance Sheet > payables
229519
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
229519
Quarters > 0 > balance Sheet > equity
807653
Quarters > 0 > balance Sheet > currency_symbol
GBP
Quarters > 0 > cash Flow > net Income
-376668
Quarters > 0 > cash Flow > depreciation
14583
Quarters > 0 > cash Flow > change In Working Capital
-3.52
Quarters > 0 > cash Flow > cash From Operations
-391049
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
468750
Quarters > 0 > cash Flow > net Change In Cash
77701
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.0002735818853866527
Quarters > 0 > ratios > PB
0.4628546170199331
Quarters > 0 > ratios > ROE
-0.046554646611849396
Quarters > 0 > ratios > ROA
-0.03625242486299283
Quarters > 0 > ratios > FCF
-391049
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
41
Quarters > 1 > quarter
2024-09-30
Quarters > 1 > income Statement > revenue
-
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
3643648.48
Quarters > 1 > income Statement > operating Income
-3643648.48
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-3643648.48
Quarters > 1 > income Statement > net Income
-3638088.04
Quarters > 1 > income Statement > eps
-0.004623128859926906
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
786932000
Quarters > 1 > income Statement > income Tax Expense
-5560.43
Quarters > 1 > income Statement > EBITDA
-476943.84
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
20210
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
59127
Quarters > 1 > balance Sheet > property Plant Equipment
0
Quarters > 1 > balance Sheet > total Assets
970538
Quarters > 1 > balance Sheet > payables
32908
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
254967
Quarters > 1 > balance Sheet > equity
715571
Quarters > 1 > balance Sheet > currency_symbol
GBP
Quarters > 1 > cash Flow > net Income
-3638088.04
Quarters > 1 > cash Flow > depreciation
29145.34
Quarters > 1 > cash Flow > change In Working Capital
65485.22
Quarters > 1 > cash Flow > cash From Operations
-331719.69
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
149545
Quarters > 1 > cash Flow > net Change In Cash
20210
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-0.004623128859926906
Quarters > 1 > ratios > PB
299.12545924862803
Quarters > 1 > ratios > ROE
-508.4174791879492
Quarters > 1 > ratios > ROA
-374.8527146798992
Quarters > 1 > ratios > FCF
-331719.69
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
35
Quarters > 2 > quarter
2024-03-31
Quarters > 2 > income Statement > revenue
-
Quarters > 2 > income Statement > cost Of Revenue
8507
Quarters > 2 > income Statement > gross Profit
-8507
Quarters > 2 > income Statement > operating Expenses
242.53
Quarters > 2 > income Statement > operating Income
-242.53
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-242.53
Quarters > 2 > income Statement > net Income
-242.53
Quarters > 2 > income Statement > eps
-3.2040626960123633e-7
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
756945238
Quarters > 2 > income Statement > income Tax Expense
3
Quarters > 2 > income Statement > EBITDA
-234.02
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
1
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
183522
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
98478
Quarters > 2 > balance Sheet > inventories
-98478
Quarters > 2 > balance Sheet > total Current Assets
282000
Quarters > 2 > balance Sheet > property Plant Equipment
0
Quarters > 2 > balance Sheet > total Assets
4354770
Quarters > 2 > balance Sheet > payables
252719
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
252719
Quarters > 2 > balance Sheet > equity
4102051
Quarters > 2 > balance Sheet > currency_symbol
GBP
Quarters > 2 > cash Flow > net Income
-242.53
Quarters > 2 > cash Flow > depreciation
8.51
Quarters > 2 > cash Flow > change In Working Capital
35.72
Quarters > 2 > cash Flow > cash From Operations
-168.57
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
149.55
Quarters > 2 > cash Flow > net Change In Cash
183.52
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-3.2040626960123633e-7
Quarters > 2 > ratios > PB
50.19174669841989
Quarters > 2 > ratios > ROE
-0.005912408207504002
Quarters > 2 > ratios > ROA
-0.00556929527851069
Quarters > 2 > ratios > FCF
-168.57
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
35
Quarters > 3 > quarter
2023-09-30
Quarters > 3 > income Statement > revenue
-
Quarters > 3 > income Statement > cost Of Revenue
18343
Quarters > 3 > income Statement > gross Profit
-18343
Quarters > 3 > income Statement > operating Expenses
262685
Quarters > 3 > income Statement > operating Income
-281030
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-281029
Quarters > 3 > income Statement > net Income
-235358
Quarters > 3 > income Statement > eps
-0.0003204132023651754
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
734545263
Quarters > 3 > income Statement > income Tax Expense
-45670
Quarters > 3 > income Statement > EBITDA
-262685
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
0.91
Quarters > 3 > income Statement > currency_symbol
GBP
Quarters > 3 > balance Sheet > cash
202548
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
116280
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
336747
Quarters > 3 > balance Sheet > property Plant Equipment
-
Quarters > 3 > balance Sheet > total Assets
4418024
Quarters > 3 > balance Sheet > payables
222990
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
222990
Quarters > 3 > balance Sheet > equity
4195034
Quarters > 3 > balance Sheet > currency_symbol
GBP
Quarters > 3 > cash Flow > net Income
-235358
Quarters > 3 > cash Flow > depreciation
18343
Quarters > 3 > cash Flow > change In Working Capital
-
Quarters > 3 > cash Flow > cash From Operations
36687
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
-
Quarters > 3 > cash Flow > net Change In Cash
-56711
Quarters > 3 > cash Flow > currency_symbol
GBP
Quarters > 3 > ratios > PE
-0.0003204132023651754
Quarters > 3 > ratios > PB
47.62686346189328
Quarters > 3 > ratios > ROE
-5.6103955295713925
Quarters > 3 > ratios > ROA
-5.327223211100709
Quarters > 3 > ratios > FCF
36687
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
36
Annuals > 0 > quarter
2024-09-30
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
0
Annuals > 0 > income Statement > gross Profit
0
Annuals > 0 > income Statement > operating Expenses
3647053
Annuals > 0 > income Statement > operating Income
-3647053
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-3647053
Annuals > 0 > income Statement > net Income
-3641487
Annuals > 0 > income Statement > eps
-0.004627448114957836
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
786932000
Annuals > 0 > income Statement > income Tax Expense
-5566
Annuals > 0 > income Statement > EBITDA
-477187
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-
Annuals > 0 > income Statement > currency_symbol
GBP
Annuals > 0 > balance Sheet > cash
20210
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
59127
Annuals > 0 > balance Sheet > property Plant Equipment
0
Annuals > 0 > balance Sheet > total Assets
970538
Annuals > 0 > balance Sheet > payables
32908
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
254967
Annuals > 0 > balance Sheet > equity
715571
Annuals > 0 > balance Sheet > currency_symbol
GBP
Annuals > 0 > cash Flow > net Income
-3641487
Annuals > 0 > cash Flow > depreciation
29166
Annuals > 0 > cash Flow > change In Working Capital
65483
Annuals > 0 > cash Flow > cash From Operations
-331883
Annuals > 0 > cash Flow > capital Expenditures
0
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
149545
Annuals > 0 > cash Flow > net Change In Cash
-182338
Annuals > 0 > cash Flow > currency_symbol
GBP
Annuals > 0 > ratios > PE
-0.004627448114957836
Annuals > 0 > ratios > PB
282.62956995182867
Annuals > 0 > ratios > ROE
-508.89247887351496
Annuals > 0 > ratios > ROA
-375.202928684915
Annuals > 0 > ratios > FCF
-331883
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
26
Annuals > 1 > quarter
2023-09-30
Annuals > 1 > income Statement > revenue
-
Annuals > 1 > income Statement > cost Of Revenue
36749
Annuals > 1 > income Statement > gross Profit
-36749
Annuals > 1 > income Statement > operating Expenses
618648
Annuals > 1 > income Statement > operating Income
-618648
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-618648
Annuals > 1 > income Statement > net Income
-572978
Annuals > 1 > income Statement > eps
-0.0007963978639594586
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
719462000
Annuals > 1 > income Statement > income Tax Expense
-45670
Annuals > 1 > income Statement > EBITDA
-581899
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-23701
Annuals > 1 > income Statement > currency_symbol
GBP
Annuals > 1 > balance Sheet > cash
202548
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
116280
Annuals > 1 > balance Sheet > inventories
-116280
Annuals > 1 > balance Sheet > total Current Assets
336747
Annuals > 1 > balance Sheet > property Plant Equipment
-
Annuals > 1 > balance Sheet > total Assets
4418024
Annuals > 1 > balance Sheet > payables
69774
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
222990
Annuals > 1 > balance Sheet > equity
4195034
Annuals > 1 > balance Sheet > currency_symbol
GBP
Annuals > 1 > cash Flow > net Income
-572978
Annuals > 1 > cash Flow > depreciation
36749
Annuals > 1 > cash Flow > change In Working Capital
88495
Annuals > 1 > cash Flow > cash From Operations
-546232
Annuals > 1 > cash Flow > capital Expenditures
2
Annuals > 1 > cash Flow > cash From Investing
33333
Annuals > 1 > cash Flow > cash From Financing
189790
Annuals > 1 > cash Flow > net Change In Cash
-204836
Annuals > 1 > cash Flow > currency_symbol
GBP
Annuals > 1 > ratios > PE
-0.0007963978639594586
Annuals > 1 > ratios > PB
44.07633740274811
Annuals > 1 > ratios > ROE
-13.658482863309333
Annuals > 1 > ratios > ROA
-12.969101118509089
Annuals > 1 > ratios > FCF
-546234
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
34
Annuals > 2 > quarter
2023-03-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
0
Annuals > 2 > income Statement > gross Profit
0
Annuals > 2 > income Statement > operating Expenses
761299
Annuals > 2 > income Statement > operating Income
-761299
Annuals > 2 > income Statement > interest Expense
0
Annuals > 2 > income Statement > pretax Income
-761299
Annuals > 2 > income Statement > net Income
-760136
Annuals > 2 > income Statement > eps
-0.0012701794484558855
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
598447724
Annuals > 2 > income Statement > income Tax Expense
-1163
Annuals > 2 > income Statement > EBITDA
-724404
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-
Annuals > 2 > income Statement > currency_symbol
GBP
Annuals > 2 > balance Sheet > cash
259259
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
128547
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
387806
Annuals > 2 > balance Sheet > property Plant Equipment
0
Annuals > 2 > balance Sheet > total Assets
4501759
Annuals > 2 > balance Sheet > payables
273555
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
273555
Annuals > 2 > balance Sheet > equity
4228204
Annuals > 2 > balance Sheet > currency_symbol
GBP
Annuals > 2 > cash Flow > net Income
-760136
Annuals > 2 > cash Flow > depreciation
36895
Annuals > 2 > cash Flow > change In Working Capital
105585
Annuals > 2 > cash Flow > cash From Operations
-433097
Annuals > 2 > cash Flow > capital Expenditures
0
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
228261
Annuals > 2 > cash Flow > net Change In Cash
-204836
Annuals > 2 > cash Flow > currency_symbol
GBP
Annuals > 2 > ratios > PE
-0.0012701794484558855
Annuals > 2 > ratios > PB
36.37503419134933
Annuals > 2 > ratios > ROE
-17.977751310012476
Annuals > 2 > ratios > ROA
-16.88531083072195
Annuals > 2 > ratios > FCF
-433097
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
26
Annuals > 3 > quarter
2022-03-31
Annuals > 3 > income Statement > revenue
50000
Annuals > 3 > income Statement > cost Of Revenue
38671
Annuals > 3 > income Statement > gross Profit
11329
Annuals > 3 > income Statement > operating Expenses
1281601
Annuals > 3 > income Statement > operating Income
-1270270
Annuals > 3 > income Statement > interest Expense
0
Annuals > 3 > income Statement > pretax Income
-1270272
Annuals > 3 > income Statement > net Income
-1108993
Annuals > 3 > income Statement > eps
-0.0018531159122596981
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
598447724
Annuals > 3 > income Statement > income Tax Expense
-161279
Annuals > 3 > income Statement > EBITDA
-1233296
Annuals > 3 > income Statement > operating Margin
-2540.54
Annuals > 3 > income Statement > total Other Income Expense Net
-2
Annuals > 3 > income Statement > currency_symbol
GBP
Annuals > 3 > balance Sheet > cash
464095
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
332938
Annuals > 3 > balance Sheet > inventories
-332938
Annuals > 3 > balance Sheet > total Current Assets
824974
Annuals > 3 > balance Sheet > property Plant Equipment
438
Annuals > 3 > balance Sheet > total Assets
4975823
Annuals > 3 > balance Sheet > payables
12351
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
237861
Annuals > 3 > balance Sheet > equity
4737962
Annuals > 3 > balance Sheet > currency_symbol
GBP
Annuals > 3 > cash Flow > net Income
-1108993
Annuals > 3 > cash Flow > depreciation
36976
Annuals > 3 > cash Flow > change In Working Capital
-254103
Annuals > 3 > cash Flow > cash From Operations
-1345667
Annuals > 3 > cash Flow > capital Expenditures
0
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
139982
Annuals > 3 > cash Flow > net Change In Cash
-1205685
Annuals > 3 > cash Flow > currency_symbol
GBP
Annuals > 3 > ratios > PE
-0.0018531159122596981
Annuals > 3 > ratios > PB
32.461439131001896
Annuals > 3 > ratios > ROE
-23.40654061809698
Annuals > 3 > ratios > ROA
-22.28762960418809
Annuals > 3 > ratios > FCF
-1345667
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-26.91334
Annuals > 3 > health Score
27
Valuation > metrics > PE
-0.0002735818853866527
Valuation > metrics > PB
0.4628546170199331
Valuation > final Score
70
Valuation > verdict
53.7% Undervalued
Profitability > metrics > ROE
-0.046554646611849396
Profitability > metrics > ROA
-0.2679131277432594
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.2841802110559857
Risk > metrics > Interest Coverage
-26.857142857142858
Risk > final Score
-47
Risk > verdict
High
Liquidity > metrics > Current Ratio
0.6114700743729278
Liquidity > metrics > Quick Ratio
0.6114700743729278
Liquidity > final Score
41
Liquidity > verdict
Weak
Prev Valuations > 0
20
Prev Valuations > 1
20
Prev Valuations > 2
20
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
55
Prev Risks > 1
-54
Prev Risks > 2
-1
Prev Liquidities > 0
95
Prev Liquidities > 1
78
Prev Liquidities > 2
88
Updated At
2026-01-20T23:02:56.657Z
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Stock Price
GBp 0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-03-31)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Nuformix plc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-03-31)
(Last Updated 2025-03-31)
Revenue
£ 0
Cost Of Revenue
£ 0
Gross Profit
£ 0
Operating Expenses
£ 0
Operating Income
£ 0
Interest Expense
£ 0
Pretax Income
£ 0
Net Income
£ 0
Income Tax Expense
£ 0
EBITDA
£ 0
Total Other Income Expense Net
£ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-03-31)
Cash
£ 0
Short Term Investments
£ 0
Receivables
£ 0
Inventories
£ 0
Total Current Assets
£ 0
Property Plant Equipment
£ 0
Total Assets
£ 0
Payables
£ 0
Short Term Debt
£ 0
Long Term Debt
£ 0
Total Liabilities
£ 0
Equity
£ 0
(Last Updated 2025-03-31)
Net Income
£ 0
Depreciation
£ 0
Change In Working Capital
£ 0
Cash From Operations
£ 0
Capital Expenditures
£ 0
Cash From Investing
£ 0
Cash From Financing
£ 0
Net Change In Cash
£ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.